Tendease 50000 IU/100g Gel for Horses הממלכה המאוחדת - אנגלית - HMA (Heads of Medicines Agencies)

tendease 50000 iu/100g gel for horses

eurovet animal health - heparin sodium 500 iu, hydroxyethyl salicylate 50 mg/g, levomenthol 5 mg/g - gel - horses food - preparations with salicylic acid derivatives, combinations

Tendease גרמניה - אנגלית - HMA (Heads of Medicines Agencies)

tendease

eurovet animal health - heparin sodium 500 iu, hydroxyethyl salicylate 50 mg/g, levomenthol 5 mg/g - gel - horses food - preparations with salicylic acid derivatives, combinations

Tendease הולנד - אנגלית - HMA (Heads of Medicines Agencies)

tendease

eurovet animal health - heparin sodium 500 iu, hydroxyethyl salicylate 50 mg/g, levomenthol 5 mg/g - gel - horses food - preparations with salicylic acid derivatives, combinations

HEPARIN SODIUM PANPHARMA 5000 IUML ישראל - אנגלית - Ministry of Health

heparin sodium panpharma 5000 iuml

pharmalogic ltd - heparin sodium - solution for injection / infusion - heparin sodium 5000 iu/ml - heparin - heparin - • prevention of thromboembolic disorders• as part of the treatment of venous or arterial thromboembolic disorders (including the early treatment of heart attacks as well as unstable angina pectoris)• for anticoagulation during treatment or operation with an extracorporeal circulation (e.g. heart/lung machine, hemodialysis)

Tendease 50,000 IU/100 g Gel for Horses הממלכה המאוחדת - אנגלית - VMD (Veterinary Medicines Directorate)

tendease 50,000 iu/100 g gel for horses

eurovet animal health b.v. - heparin sodium, hydroxyethyl salicylate, menthol levo - gel - anti inflammatory - horses

innohep- tinzaparin sodium injection ארצות הברית - אנגלית - NLM (National Library of Medicine)

innohep- tinzaparin sodium injection

celgene corporation - tinzaparin sodium (unii: 3s182et3ua) (tinzaparin - unii:7uq7x4y489) - injection - 20000 [iu] in 1 ml - innohep® is indicated for the treatment of acute symptomatic deep vein thrombosis with or without pulmonary embolism when administered in conjunction with warfarin sodium. the safety and effectiveness of innohep® were established in hospitalized patients. innohep® is contraindicated in patients with active major bleeding, in patients with (or history of) heparin-induced thrombocytopenia, or in patients with hypersensitivity to tinzaparin sodium. innohep® is contraindicated in patients aged 90 years or older with creatinine clearance ≤ 60 ml/min. patients with known hypersensitivity to heparin, sulfites, benzyl alcohol, or pork products should not be treated with innohep®.